CD274 and cancer: Currently, marketing ICIs that target PD-1/PD-L1 include pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, and durvalumab, which are either approved for clinical use or under clinical investigation in various cancer types.